M Agulnik1, R L B Costa1, M Milhem2, A W Rademaker1, B C Prunder3, D Daniels3, B T Rhodes3, C Humphreys1, S Abbinanti1, L Nye1, R Cehic1, A Polish1, C Vintilescu1, T McFarland4, K Skubitz5, S Robinson6, S Okuno6, B A Van Tine3. 1. Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, USA. 2. Division of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa City, USA. 3. Division of Hematology/Oncology, Washington University in St. Louis, St Louis, USA. 4. Division of Hematology/Oncology, University of Wisconsin, Madison, USA. 5. Division of Hematology/Oncology, University of Minnesota, Minneapolis, USA. 6. Division of Hematology/Oncology, Mayo Clinic, Rochester, USA.
Abstract
Background: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/β and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies. Patients and methods: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5 mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity. Results: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRα/β or FGF, and activity of tivozanib. Conclusion: Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS. Clinical Trial Number: NCT01782313.
Background: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/β and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies. Patients and methods: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5 mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity. Results: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRα/β or FGF, and activity of tivozanib. Conclusion:Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS. Clinical Trial Number: NCT01782313.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: S Arita; F Kikkawa; H Kajiyama; K Shibata; M Kawai; K Mizuno; T Nagasaka; K Ino; S Nomura Journal: Int J Gynecol Cancer Date: 2005 Mar-Apr Impact factor: 3.437
Authors: Dmitry A Nosov; Brooke Esteves; Oleg N Lipatov; Alexei A Lyulko; A A Anischenko; Raju T Chacko; Dinesh C Doval; Andrew Strahs; William J Slichenmyer; Pankaj Bhargava Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544
Authors: Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Paul Lorigan; Jaap Verweij; Zsuzsa Papai; Sjoerd Rodenhuis; Axel Le Cesne; Michael G Leahy; John A Radford; Martine M Van Glabbeke; Anne Kirkpatrick; Pancras C W Hogendoorn; Jean-Yves Blay Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Evan Rosenbaum; Cristina R Antonescu; Shaleigh Smith; Martina Bradic; Daniel Kashani; Allison L Richards; Mark Donoghue; Ciara M Kelly; Benjamin Nacev; Jason E Chan; Ping Chi; Mark A Dickson; Mary L Keohan; Mrinal M Gounder; Sujana Movva; Viswatej Avutu; Katherine Thornton; Ahmet Zehir; Anita S Bowman; Samuel Singer; William Tap; Sandra D'Angelo Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469